Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives throughout more than 100 countries. Valeant’s primary focus is in the areas of dermatology and eye health. Valeant has an established portfolio of durable products and our strategy is to focus the business on core geographies and therapeutic areas that offer high-growth opportunities. Another critical element of our strategy is business development. We have completed numerous transactions over the past few years, including the acquisition of international eye health organization Bausch + Lomb in 2013, to expand our portfolio and our geographic footprint. We will continue to pursue value-added business development opportunities as they arise. Valeant’s strategic markets are primarily in the United States, Canada, Europe, the Middle East, Latin America, Asia Pacific and Africa.
Company Growth (employees)
Type
Public
HQ
Aliso Viejo, US
Founded
1960
Size (employees)
21,500 (est)-2%
Valeant Pharmaceuticals International was founded in 1960 and is headquartered in Aliso Viejo, US

Key People at Valeant Pharmaceuticals International

Joe Papa

Joe Papa

CEO

Valeant Pharmaceuticals International Office Locations

Valeant Pharmaceuticals International has an office in Aliso Viejo

Valeant Pharmaceuticals International Metrics

Valeant Pharmaceuticals International Financial Metrics

Revenue (2016)

$9.7 b

Revenue growth (2015-16), %

(7%)

Net income (2016)

($2.4 b)

Market capitalization (21-Mar-2017)

$3.7 b

Closing share price (21-Mar-2017)

$10.6

Cash (31-Dec-2016)

$542 m
Valeant Pharmaceuticals International's current market capitalization is $3.7 b.
Valeant Pharmaceuticals International's revenue was reported to be $9.7 b in FY, 2016 which is a 7.4% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$5.8 b$8.3 b$10.4 b$9.7 b

Revenue growth, %

43%26%(7%)

Cost of goods sold

$1.8 b

Gross profit

$3.9 b$6.1 b$7.9 b

Gross profit Margin, %

68%73%76%

Operating expense total

$4.3 b$4 b$6.4 b

EBIT

($409.5 m)$2 b$1.5 b

EBIT margin, %

(7%)25%15%

Interest expense

$844.3 m

Interest income

$8 m

Net Income

($863.7 m)$912.2 m($287.8 m)($2.4 b)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$600.3 m$322.6 m$597.3 m$542 m

Accounts Receivable

$1.8 b$2.1 b$2.7 b$2.5 b

Inventories

$205 m$641.9 m$966.4 m$696 m

Current Assets

$3.9 b$4.2 b$5.5 b$5.1 b

PP&E

$1.2 b$1.3 b$1.4 b$1.3 b

Goodwill

$9.8 b$9.3 b$18.6 b$15.8 b

Total Assets

$28 b$26.4 b$49 b$43.5 b

Accounts Payable

$327 m$398 m$433.7 m$324 m

Total Debt

$17.4 b$15.3 b$31.1 b

Current Liabilities

$2.5 b$2.7 b$5.3 b$3.6 b

Additional Paid-in Capital

$228.9 m$243.9 m$304.9 m$351 m

Retained Earnings

($3.3 b)($2.4 b)($2.7 b)($5.1 b)

Total Equity

$5.2 b$5.4 b$6 b$3.3 b

Debt to Equity Ratio

3.3 x2.8 x5.2 x

Debt to Assets Ratio

0.6 x0.6 x0.6 x

Financial Leverage

5.3 x4.8 x8.1 x13.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($863.7 m)$912.2 m($287.8 m)($2.4 b)

Accounts Receivable

($260 m)

Inventories

($120 m)($170 m)($280 m)($160 m)

Accounts Payable

Cash From Operating Activities

$1 b$2.3 b$2.2 b$2.1 b

Purchases of PP&E

($115.3 m)($291.6 m)($235.2 m)($235 m)

Cash From Investing Activities

($5.4 b)($99.7 m)($15.6 b)($125 m)

Long-term Borrowings

($6.3 b)($3.9 b)($2.1 b)($2.4 b)

Cash From Financing Activities

$4 b($2.4 b)$13.7 b($2 b)

Valeant Pharmaceuticals International Market Value History

Valeant Pharmaceuticals International Online Presence

Valeant Pharmaceuticals International News

Valeant Pharmaceuticals International Company Life

You may also be interested in